Coronary heart disease in diabetes mellitus: Risk factors and epidemiology;A Doença coronária na diabetes mellitus. Factores de risco e epidemiologia

Revista Portuguesa de Cardiologia

Volumn 23, Issue 10, 2004, Pages 1359-1366

  Vaz Carneiro, António ^a  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Cardiovascular risk factors; Evidence based cardiology; Primary and seconding prevention of coronary heart disease; Type 1 and 2 diabetes mellitus

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; WARFARIN;

ARTICLE; CARDIOVASCULAR RISK; DIABETIC MICROANGIOPATHY; DIET THERAPY; EXERCISE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; SMOKING; SMOKING CESSATION; SYSTEMATIC REVIEW; TREATMENT PLANNING;

CORONARY DISEASE; DIABETES COMPLICATIONS; FEMALE; HUMANS; MALE; RISK FACTORS;

EID: 10644240107     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Gerstein HC, Haynes RB, editors. Evidence-Based Diabetes Care. Hamilton: BC Decker Inc., 2001
2. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart LaBI. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): Final report. Circulation 2002;106:3143.
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-4.
4. Stein B, Weintraub WS, Gebhart SSP, Cohen-Bernstein CL, Grosswald R, Liberman HA, Douglas JSJ, Morris DC, King SB, III. Influence of Diabetes Mellitus on Early and Late Outcome After Percutaneous Transluminal Coronary Angioplasty. Circulation 1995;91:979-89.
5. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins a-i and b, and HDL density subfractions: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 2001;104:1108-13.
6. Milan Study on Atherosclerosis and Diabetes (MiSAD) Group. Prevalence of unrecognized silent myocardial ischemia and its association with atherosclerotic risk factors in noninsulin-dependent diabetes mellitus. Am J Cardiol 1997;79:134-9.
7. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22:233-40.
8. Qiao Q, Pyorala K, Pyorala M, Nissinen A, Lindstrom J, Tilvis R, Tuomilehto J. Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur Heart J 2002;23:1267-75.
9. The DCCT Research Group. Lipid and lipoprotein levels in patients with IDDM diabetes control and complication. Trial experience. Diabetes Care 1992;15:886-94.
10. Lu W, Resnick HE, Jablonski KA, Jones KL, Jain AK, Howard WJ, Robbins DC, Howard BV. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care 2004;26:16-23.
11. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
12. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
13. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil NA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.
14. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998-3007.
15. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjekshus J, Kristinsson A, McInnes GT, Mehlsen J, Nieminen MS, O'Brian E, Östergren J, for the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
16. Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. Journal of Hypertension 1993;11:309-17.
17. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412-9.
18. Mogensen CE, Hansen KW, Pedersen MM, Christensen CK. Renal factors influencing blood pressure threshold and choice of treatment for hypertension in IDDM. Diabetes Care 1991;14 (suppl):13-26.
19. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.
20. Al-Delaimy WK, Manson JE, Solomon CG, Kawachi I, Stamfer MJ, Willet WC, Hu FB. Smoking and risk of coronary heart disease among women with type 2 diabetes mellitus. Arch Intern Med 2002;162:273-9.
21. Yudkin JS. How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects. BMJ 1993;306:1313-8.
22. Moy CS, LaPorte RE, Dorman JS, Songer TJ, Orchard TJ, Kuller LH, Becker DJ, Drash AL. Insulin-dependent diabetes mellitus mortality. The risk of cigarette smoking. Circulation 1990;82:37-43.
23. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.
24. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S, for the LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10.
25. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225-32.
26. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995;75:894-903.
27. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
28. Costa J, Borges M, Oliveira E, Gouveia M, Carneiro AV. Incidência e prevalência da hipercolesterolémia em Portugal: uma revisão sistemática da literatura. Parte I. Rev Port Cardiol 2003;22:569-77.
29. Costa J, Borges M, Oliveira E, Gouveia M, Carneiro AV. Incidência e prevalência da hipercolésterolémia em Portugal: uma revisão sistemática da literatura. Parte II. Rev Port Cardiol 2003;22:683-702.
30. Yusuf S, Cairns JA, Camm AJ, Fallen EL, Gersh BJ, editors. Evidence Based Cardiology. London: BMJ, 1998
31. Carneiro AV. A terapêutica com estatinas na prevenção primária e secundária da doença coronária. Revisão científica. Rev Port Cardiol 2004;23:95-122.
32. Soares I, Carneiro AV. Prevenção e rastreio. Parte I - Princípios gerais. Rev Port Cardiol 2002;21:1505-17.
33. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction. N Engl J Med 1998;339:229-34.
34. Gluckman TJ, Baranowski B, Ashen D, Henrikson CA, McAllister M, Braunstein JB, Blumenthal RS. A practical and evidence-based approach to cardiovascular disease risk reduction. Arch Intern Med 2004;164:1490-500.
35. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes. N Engl J Med 2003;348:383-93.